The lived experience of interferon-free treatments for hepatitis C: a thematic analysis

David Whitely , Anne Whittaker, Lawrie Elliott, Sarah Cunningham Burley

Research output: Contribution to journalArticle

9 Downloads (Pure)

Abstract

BACKGROUND: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has tended to focus on improving outcomes, shortened treatment length and reduced side-effects of interferon-free regimens. How these treatments are being understood and experienced by the people receiving them has so far been overlooked. This study therefore aimed to explore the lived experience of individuals taking interferon-free HCV therapies.
METHODS: Data were generated through 16 semi-structured interviews with a purposive sample of eight participants, recruited from a university hospital in Scotland. The interviews took place between June 2015 and March 2016, before and after a period of interferon-free HCV treatment. The data was interrogated using a thematic analysis, underpinned by social phenomenological theory.
RESULTS: Three overriding themes were identified. ‘Expectations and realisations’ characterised the influence that interferon continued to cast over interferon-free treatment, contrasting the practicalities of taking interferon-free therapy with preconceived notions. ‘An honour and a pleasure’ portrayed a positive experience of an undemanding therapy, yet amongst those with a history of drug use, was also positioned as a privilege, associated with feelings of luck and guilt. ‘Treatment needs’ illustrated the strategies participants used to search for treatment efficacy, and the value those with a significant history of drug use placed on support. One nonconforming case is then discussed to enhance rigour and trustworthiness.
CONCLUSION: This is the first qualitative exploration of the experience of interferon-free HCV treatment reported globally. The results from this study suggest a cultural lag exists between the pharmacological developments which have been witnessed, and societal understandings of them. This has implications for the way services meet the needs of, and offer therapy to, HCV positive individuals.
Original languageEnglish
Pages (from-to)21–28
Number of pages8
JournalInternational Journal of Drug Policy
Volume38
Early online date11 Nov 2016
DOIs
Publication statusPublished - Dec 2016

Fingerprint

Hepatitis C
Interferons
Hepacivirus
Therapeutics
Interviews
Pleasure
Guilt
Scotland
Pharmaceutical Preparations
Emotions
Pharmacology

Keywords

  • interferon
  • hepatitis C
  • virology

Cite this

Whitely , David ; Whittaker, Anne ; Elliott, Lawrie ; Cunningham Burley, Sarah . / The lived experience of interferon-free treatments for hepatitis C: a thematic analysis. In: International Journal of Drug Policy. 2016 ; Vol. 38. pp. 21–28.
@article{6def15cbd9cc44d38c4264ad2e4618b8,
title = "The lived experience of interferon-free treatments for hepatitis C: a thematic analysis",
abstract = "BACKGROUND: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has tended to focus on improving outcomes, shortened treatment length and reduced side-effects of interferon-free regimens. How these treatments are being understood and experienced by the people receiving them has so far been overlooked. This study therefore aimed to explore the lived experience of individuals taking interferon-free HCV therapies.METHODS: Data were generated through 16 semi-structured interviews with a purposive sample of eight participants, recruited from a university hospital in Scotland. The interviews took place between June 2015 and March 2016, before and after a period of interferon-free HCV treatment. The data was interrogated using a thematic analysis, underpinned by social phenomenological theory.RESULTS: Three overriding themes were identified. ‘Expectations and realisations’ characterised the influence that interferon continued to cast over interferon-free treatment, contrasting the practicalities of taking interferon-free therapy with preconceived notions. ‘An honour and a pleasure’ portrayed a positive experience of an undemanding therapy, yet amongst those with a history of drug use, was also positioned as a privilege, associated with feelings of luck and guilt. ‘Treatment needs’ illustrated the strategies participants used to search for treatment efficacy, and the value those with a significant history of drug use placed on support. One nonconforming case is then discussed to enhance rigour and trustworthiness.CONCLUSION: This is the first qualitative exploration of the experience of interferon-free HCV treatment reported globally. The results from this study suggest a cultural lag exists between the pharmacological developments which have been witnessed, and societal understandings of them. This has implications for the way services meet the needs of, and offer therapy to, HCV positive individuals.",
keywords = "interferon, hepatitis C, virology",
author = "David Whitely and Anne Whittaker and Lawrie Elliott and {Cunningham Burley}, Sarah",
note = "Acceptance date from journal webpage AAM: 12m embargo Author was at Napier when article was accepted. Napier confirmed file uploaded within deadline and date ET 3/10/18 https://www.napier.ac.uk/research-and-innovation/research-search/outputs/the-lived-experience-of-interferonfree-treatments-for-hepatitis-c-a-thematic-analysis",
year = "2016",
month = "12",
doi = "10.1016/j.drugpo.2016.10.013",
language = "English",
volume = "38",
pages = "21–28",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier B.V.",

}

The lived experience of interferon-free treatments for hepatitis C: a thematic analysis. / Whitely , David; Whittaker, Anne; Elliott, Lawrie; Cunningham Burley, Sarah .

In: International Journal of Drug Policy, Vol. 38, 12.2016, p. 21–28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The lived experience of interferon-free treatments for hepatitis C: a thematic analysis

AU - Whitely , David

AU - Whittaker, Anne

AU - Elliott, Lawrie

AU - Cunningham Burley, Sarah

N1 - Acceptance date from journal webpage AAM: 12m embargo Author was at Napier when article was accepted. Napier confirmed file uploaded within deadline and date ET 3/10/18 https://www.napier.ac.uk/research-and-innovation/research-search/outputs/the-lived-experience-of-interferonfree-treatments-for-hepatitis-c-a-thematic-analysis

PY - 2016/12

Y1 - 2016/12

N2 - BACKGROUND: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has tended to focus on improving outcomes, shortened treatment length and reduced side-effects of interferon-free regimens. How these treatments are being understood and experienced by the people receiving them has so far been overlooked. This study therefore aimed to explore the lived experience of individuals taking interferon-free HCV therapies.METHODS: Data were generated through 16 semi-structured interviews with a purposive sample of eight participants, recruited from a university hospital in Scotland. The interviews took place between June 2015 and March 2016, before and after a period of interferon-free HCV treatment. The data was interrogated using a thematic analysis, underpinned by social phenomenological theory.RESULTS: Three overriding themes were identified. ‘Expectations and realisations’ characterised the influence that interferon continued to cast over interferon-free treatment, contrasting the practicalities of taking interferon-free therapy with preconceived notions. ‘An honour and a pleasure’ portrayed a positive experience of an undemanding therapy, yet amongst those with a history of drug use, was also positioned as a privilege, associated with feelings of luck and guilt. ‘Treatment needs’ illustrated the strategies participants used to search for treatment efficacy, and the value those with a significant history of drug use placed on support. One nonconforming case is then discussed to enhance rigour and trustworthiness.CONCLUSION: This is the first qualitative exploration of the experience of interferon-free HCV treatment reported globally. The results from this study suggest a cultural lag exists between the pharmacological developments which have been witnessed, and societal understandings of them. This has implications for the way services meet the needs of, and offer therapy to, HCV positive individuals.

AB - BACKGROUND: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has tended to focus on improving outcomes, shortened treatment length and reduced side-effects of interferon-free regimens. How these treatments are being understood and experienced by the people receiving them has so far been overlooked. This study therefore aimed to explore the lived experience of individuals taking interferon-free HCV therapies.METHODS: Data were generated through 16 semi-structured interviews with a purposive sample of eight participants, recruited from a university hospital in Scotland. The interviews took place between June 2015 and March 2016, before and after a period of interferon-free HCV treatment. The data was interrogated using a thematic analysis, underpinned by social phenomenological theory.RESULTS: Three overriding themes were identified. ‘Expectations and realisations’ characterised the influence that interferon continued to cast over interferon-free treatment, contrasting the practicalities of taking interferon-free therapy with preconceived notions. ‘An honour and a pleasure’ portrayed a positive experience of an undemanding therapy, yet amongst those with a history of drug use, was also positioned as a privilege, associated with feelings of luck and guilt. ‘Treatment needs’ illustrated the strategies participants used to search for treatment efficacy, and the value those with a significant history of drug use placed on support. One nonconforming case is then discussed to enhance rigour and trustworthiness.CONCLUSION: This is the first qualitative exploration of the experience of interferon-free HCV treatment reported globally. The results from this study suggest a cultural lag exists between the pharmacological developments which have been witnessed, and societal understandings of them. This has implications for the way services meet the needs of, and offer therapy to, HCV positive individuals.

KW - interferon

KW - hepatitis C

KW - virology

U2 - 10.1016/j.drugpo.2016.10.013

DO - 10.1016/j.drugpo.2016.10.013

M3 - Article

VL - 38

SP - 21

EP - 28

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

ER -